Urgent.News

What's breaking now, across hundreds of outlets.

Finance & Markets

Johnson & Johnson Is on Track for $101 Billion in 2026 Sales. Is This Dividend King Still a Buy?

Key PointsJohnson & Johnson is a leader in the pharmaceutical and medical device sectors.

Johnson & Johnson (JNJ) continues its impressive streak of long-term performance and dividend growth. Founded over a century ago, the healthcare giant has increased its dividend for an astonishing 64 consecutive years, earning its status as a Dividend King and the longest streak among healthcare companies. Recently, J&J released its full-year guidance for 2026, projecting revenue of $101.2 billion and earnings per share of $11.10, representing modest improvements over previous estimates.

Despite this solid guidance, the stock's yield of 1.9% remains below the market average and lower than other healthcare stocks, which has deterred investors seeking maximum income. Additionally, J&J's valuation appears to be expensive, with a price-to-sales ratio of 6.8x, a price-to-earnings ratio of 42x, and a price-to-book ratio of 8.2x, all of which exceed their five-year averages.

While this high valuation may discourage value investors, Johnson & Johnson remains a strong option for conservative, income-oriented investors who appreciate consistent dividends. The stock could be considered a wish-list stock for those willing to pay a premium for quality, particularly during market downturns when valuation opportunities may arise.

However, investors seeking a diversified healthcare stock with a premium price tag and above-average yield may find that J&J does not fit their current portfolio needs. Nonetheless, for those with a long-term perspective and a value focus, J&J's reliable dividend and consistent performance make it a compelling choice.

Rewritten by urgent.news; may contain errors — check the original.

Sources: fool.com · nasdaq.com

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at nasdaq.com →

Report a problem with this story

More in Finance & Markets

More from Sunday 22 November →